project id: TCGA-TGCT; case submitter id: TCGA-XE-AAOL; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.79; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 0.11; rna integrity number: 7.2; age at index: 38; days to birth: -14230; ethnicity: not hispanic or latino; gender: male; race: black or african american; vital status: Alive; year of birth: 1970; age at diagnosis: 14230; ajcc clinical m: M0; ajcc clinical n: NX; ajcc clinical stage: Stage I; ajcc clinical t: T1; ajcc pathologic m: M0; ajcc pathologic n: NX; ajcc pathologic stage: Stage I; ajcc pathologic t: T1; ajcc staging system edition: 6th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 13.0; icd 10 code: C62.9; last known disease status: not reported; morphology: 9061/3; primary diagnosis: Seminoma, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Testis, NOS; synchronous malignancy: No; tissue or organ of origin: Testis, NOS; tumor grade: Not Reported; year of diagnosis: 2008; treatment or therapy: not reported; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 1923; days to sample procurement: 0; initial weight: 520.0; portion submitter id: TCGA-XE-AAOL-01A-11; percent lymphocyte infiltration: 60.0; percent monocyte infiltration: 20.0; percent necrosis: 0.0; percent neutrophil infiltration: 10.0; percent normal cells: 0.0; percent stromal cells: 10.0; percent tumor cells: 90.0; percent tumor nuclei: 90.0;